BioCryst sees FY25 revenue $560M-$575M, consensus $548.9M

The company said, “Based on the early signs we are seeing that many more of our Medicare patients are able to afford paid therapy in 2025, and the strong patient demand for ORLADEYO to start the year, the company has increased its full year 2025 outlook for global net ORLADEYO revenue to between $535 million and $550 million. The company now expects full year 2025 total revenue will be between $560 million and $575 million. The increased guidance for ORLADEYO revenues in 2025 also results in an increase in related operating expenses, primarily related to cost of goods sold, distribution costs and higher incentive compensation. The company reiterates the previously provided 2025 non-GAAP operating expense outlook range of $425 million to $435 million. The revenue related operating expense increases are captured at the higher end of this range.”